Effect of voxelotor on cerebral perfusion and cerebral oxygen metabolism and cardiac stress in adult patients with sickle cell disease
American Journal of Hematology · 2025
DOI: 10.1002/ajh.27522 ↗Kurz gefasst
Klinische Studie in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Kadère Konté und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Cerebrovascular Circulation, Oxygen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Sickle cell disease (SCD) is complicated by silent cerebral infarcts (SCIs), for which anemia is an important risk factor. Despite normal oxygen delivery (OD), cerebral vascular reserve (CVR), and cerebral metabolic rate of oxygen (CMRO 2 ) are diminished in SCD, possibly causing the formation of SCIs. Voxelotor inhibits polymerization by increasing the hemoglobin oxygen binding, ameliorating hemolytic anemia. Furthermore, anemia is related to cardiac complications. Our aims were to assess the effect of voxelotor on markers of cerebral perfusion, cerebral oxygen metabolism, and markers of cardiac stress in SCD patients. Cerebral hemodynamics and oxygen metabolism were measured with MRI before and after 3 months of voxelotor treatment (1500 mg/day) in 18 adults with SCD (HbSS/HbSβ 0 ‐thalassemia). Hemoglobin levels significantly increased ( p = .001) and markers of hemolysis decreased ( p < .05). OD increased from 6.5 (IQR, 6.0–7.1) mL O 2 /100 g/min to 8.1 (IQR, 7.2–8.7) mL O 2 /100 g/min ( p = .001). CBF and CVR did not change. CMRO 2 decreased from 2.0 (IQR, 1.9–2.1) mL O 2 /100 g/min to 1.9 (IQR, 1.6–2.1) mL O 2 /100 g/min ( p = .03). N‐terminal pro‐B type natriuretic peptide (NT‐proBNP) levels decreased ( p = .048) and maximum tricuspid regurgitation flow velocity (TRV max ) normalized in all but one patient with increased TRV max . Voxelotor treatment in patients with severe SCD did not decrease CBF despite increased Hb levels. Cerebral oxygen metabolism slightly decreased, despite raised OD, most likely due to drug‐induced increase in oxygen binding. Nonetheless, voxelotor improved clinically validated markers of cardiac stress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
- Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
- Division of Cardiology, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
- Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands.
ORCID-Profile: Kadère Konté, John C Wood, Bart J Biemond
Zitieren
APA
Konté, K., Afzali-Hashemi, L., Baas, K. P. A., Schrantee, A., Wood, J. C., Nur, E., Nederveen, A. J., & Biemond, B. J. (2025). Effect of voxelotor on cerebral perfusion and cerebral oxygen metabolism and cardiac stress in adult patients with sickle cell disease. American Journal of Hematology. https://doi.org/10.1002/ajh.27522
Vancouver
Konté K, Afzali-Hashemi L, Baas KPA, Schrantee A, Wood JC, Nur E, et al. Effect of voxelotor on cerebral perfusion and cerebral oxygen metabolism and cardiac stress in adult patients with sickle cell disease. American Journal of Hematology. 2025. doi:10.1002/ajh.27522
BibTeX
@article{Kont2025,
author = {Konté, Kadère and Afzali-Hashemi, Liza and Baas, Koen P A and Schrantee, Anouk and Wood, John C and Nur, Erfan and Nederveen, Aart J and Biemond, Bart J},
title = {Effect of voxelotor on cerebral perfusion and cerebral oxygen metabolism and cardiac stress in adult patients with sickle cell disease},
journal = {American Journal of Hematology},
year = {2025},
doi = {10.1002/ajh.27522}
}
EUVIMED